Actively Recruiting
Evaluating Decitabine Combined with Lisaftoclax and Olverembatinib for Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia
Led by M.D. Anderson Cancer Center · Updated on 2026-09-25
30
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the recommended doses of lisaftoclax and olverembatinib when given together with decitabine in people with advanced Chronic Myeloid Leukemia CML and Philadelphia Chromosome-Positive Acute Myeloid Leukemia Ph AML. The study aims to find safe and biologically effective dose levels and to assess treatment effects on remission rates, disease progression, and survival outcomes. It also explores how olverembatinib affects certain cell pathways and protein expressions related to leukemia. Participants receive decitabine intravenously and lisaftoclax and olverembatinib orally. The study includes two phases in Phase 1, different doses of lisaftoclax will be tested with a small group of participants to identify the best dose. In Phase 2, participants will receive the recommended dose found in Phase 1. The combination therapy is given in cycles, and dosing depends on when participants join the study. During the trial, participants will be monitored for safety and side effects over about one year. Researchers will track treatment responses through blood tests and other assessments to measure remission and disease control. Participants must agree to use contraception during and after the study. The total study period runs until early 2029, with evaluations of safety, treatment effects, and survival outcomes throughout.
CONDITIONS
Brief Title
A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia
Research Team
N
Nicholas Short, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here